NanoString nCounter Vantage 3D platform-based complementary diagnostic tests for precision medicine in pediatric cancers

Facebook
Twitter
Email
LinkedIn

Outcome

Status

Active

Competition

None

Genome Centre(s)

GE3LS

No

Project Leader(s)

Cynthia Hawkins

Fiscal Year Project Launched

2019-2020

Project Description

DNA-based next generation sequencing provides important information about DNA alterations however, most oncology drugs are designed against defined molecular targets at the protein level. There is a pressing need for novel diagnostics that interrogate all levels of cellular information, protein, RNA and DNA, in order to best guide therapeutic choices. This project aims to amalgamate proteomic data with genomic and transcriptomic information to develop laboratory developed (LDT)-complementary diagnostics for the most common pediatric cancers. Furthermore, the partnership between NanoString Technologies and the SickKids Department of Paediatric Laboratory Medicine will leverage their combined technological, clinical and business expertise.

Facebook
Twitter
Email
LinkedIn